ADH1B and ALDH Gene Variants and Lung Cancer Risk
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorKaohsiung Medical University
About this trial
Lung cancer in never-smokers is increasingly recognized as a disease influenced by genetic susceptibility. Aldehyde-metabolizing enzymes, including the ALDH gene family and ADH1B, play key roles in detoxifying reactive aldehydes that can damage DNA and promote oxidative stress. In this study, we will examine whether ten selected genetic variants, nine single nucleotide polymorphisms (SNPs) across five ALDH family genes and one variant in ADH1B are associated with the risk of lung cancer and its major subtypes. Limited epidemiological evidence is currently available on the association between these aldehyde-metabolizing gene variants and lung cancer. This research aims to clarify their potential contribution to the development of lung cancer, particularly among never-smokers.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Incident lung cancer cases confirmed by pathology and healthy adult over age of 18 years.
Disqualifiers
Individuals with incomplete data will not be included as study participants.
Trial population
Lung cancer status determined by pathology-confirmed diagnosis at the time of case identification
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Lung cancer status (case vs control)
Lung cancer status determined by pathology-confirmed diagnosis at the time of case identification
Time frame
Not applicable (baseline status)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Kaohsiung Medical University
Lead sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: